Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
3.03%
↓ 99% below average
Average (2y)
313.97%
Historical baseline
Range
High:938.88%
Low:0.00%
Volatility
299.0%
High variability
| Period | Value |
|---|---|
| 2024 | 3.03% |
| 2023 | 938.88% |
| 2022 | 0.00% |